subscribe
 

Science start-ups win funding

16th July 2018


The search for the next tranche of innovative, exciting and potentially disruptive life science start-ups, who will further the development of their ventures at the Babraham Research Campus is complete. On Wednesday 11th July, eight finalists presented to a packed lecture theatre of members of the Babraham Research Campus community, ON Helix delegates, supporters and an expert judging panel, for the chance to win access to Accelerate@Babraham's bio-incubator facilities, plus a raft of additional benefits.

Of the eight, five start-ups were chosen as the overall winners. The successful ventures are:

·       Antiverse 

·       Kalium Diagnostics

·       Oppilotech 

·       Qkine 

·      VisusNano 

The winning ventures secure access to Accelerate@Babraham's bio-incubator facilities, including use of communal equipped laboratory space, flexible workspace within the campus' stimulating and supportive environment and access to its community hub, which includes office, meeting and social spaces. In addition, each also receives: £20K non-dilutive funding; 1-2-1 mentoring from world-class scientific, technical and business experts; access to the Babraham Research Campus' highly experienced life science, healthcare, business and investor networks; access to Accelerate@Babraham's top quality programme, which will run from September to December this year and includes bespoke training sessions and a final Demo Day  all run by practitioners' expert in life science and bio-innovation.

The competition attracted a rich variety of high calibre applications, all of which were reviewed by a panel of senior academics, investors, entrepreneurs and industry leaders. After this challenging selection process, eight companies made it through to the second stage where they pitched to the competition panel and faced a quick-fire Q & A. The panel consisted of John Trainer, VP and Head, Partnering and Strategy at MedImmune, Jo Parfrey, Non-exec Director of Babraham Bioscience Technologies, David Grainger, Partner at Medicxi, Tony Kouzarides, Professor of Cancer Biology at the University of Cambridge and Derek Jones, CEO, Babraham Bioscience Technologies Ltd.

Derek Jones, CEO, Babraham Bioscience Technologies Ltd said: "It is extremely challenging to communicate a business idea, cutting-edge science, and quantify the potential and convince a panel of judges that your proposition is better than the competition, whatever the situation. However, all eight finalists did incredibly well, and we were so impressed with all the pitches that we hope to be able to offer mentoring support and useful introductions to the runners up too.

 "To those that made it through ­ we are delighted to welcome you to Accelerate@Babraham and look forward to working with you from September."

 

 





Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe